Conceptus Essure Contraceptive Approved Three Months Post-Panel Review
This article was originally published in The Gray Sheet
Executive Summary
FDA's approval of Conceptus' Essure non-incisional permanent birth control device includes a requirement that the company document the placement failure rate with newly trained physicians and identify factors associated with the failure, the agency notes in a Nov. 4 "talk paper" announcing the approval
You may also be interested in...
Expect Bayer To Get Heat At FDA Advisory Panel Over Essure Adverse Events, Doc Training
FDA’s Obstetrics and Gynecology Devices Advisory Panel will discuss risk mitigation for pain, bleeding, and other events associated with its Essure sterility device on Sept. 24. Meanwhile, Bayer’s new summary for the meeting reveals several lawsuits were filed against it “making allegations [on] clinical trials and safety,” of Essure. A Citizen Petition says altered trial patient records and violations of adverse event reporting rules by Conceptus in 2011 invalidates its PMA.
New Products In Brief
Mela Sciences launches MelaFind melanoma detection device in the U.S. Medtronic launches CapSure Sense MRI SureScan pacing leads overseas. More product news.
Conceptus, J&J/Gynecare Agreement Will Aid Essure Adoption – CEO
Conceptus will target physicians comfortable with new technology adoption through a co-promotional agreement with Johnson & Johnson/Gynecare